# Neural Omega > European infrastructure for autoimmune disease. Four products, two verticals, one foundation. Built in Madrid. Neural Omega builds the clinical, patient, and research infrastructure layer for autoimmune disease in Europe. Founded in 2025, based in Madrid, Spain. Member of AseBio (Spanish Bioindustry Association). Recognised by ENISA. Funded by CDTI (Spanish public R&D funding body). CEO and founder: Pedro Bernardo Martín-Borregón — medical background, bioinformatics research. The core thesis: autoimmune disease has been treated as dozens of isolated conditions sharing no data, no vocabulary, and no infrastructure. The biology says otherwise — shared genetics, shared mechanisms, shared therapeutic response signals. Three things now converge to make a unified European data layer possible: native clinical tools, the European Health Data Space (EHDS, effective 2029), and AI at sufficient scale. Key structural facts about autoimmune disease in Europe: - Average time from first symptoms to confirmed autoimmune diagnosis: 4.5 years (up to 7 years for ankylosing spondylitis) - 1 in 12 people worldwide live with at least one autoimmune condition - Over 500 million patients globally, most without adequate diagnostic or care support - The average autoimmune patient sees 5–7 specialists before receiving a confirmed diagnosis - Prevalence is 2–3× higher in women than men — still underresearched - 80+ distinct autoimmune diseases identified, with overlapping immunological mechanisms --- ## Products Neural Omega has four products organised in two verticals. All share a single European data layer. ### Neural Omega Health — For patients and clinicians - [Maia Clinical](https://neuralomega.com/en/health/maia-clinical): Daily clinical companion for autoimmune specialists — rheumatologists, internists, dermatologists, and gastroenterologists. Validated scoring tools, drug interaction checks for immunomodulators and biologics, evidence-based guidelines, and longitudinal disease monitoring. Native Apple app (iPad, iPhone, Mac), offline-first, GDPR-compliant. Free for clinicians — no pharma funding, no patient data sales, no advertising. Closed beta · 2026. - [Maia](https://neuralomega.com/en/health/maia): Symptom and trigger tracker for people living with autoimmune disease. Structured capture by system (joints, skin, gut, energy, mood), medication tracking for biologics and JAK inhibitors, pattern analysis over time, and structured pre-visit reports for specialists. Offline-first by default — data stays on device. Apple Health integration on user terms. Built in collaboration with patient associations for IBD, lupus, rheumatoid arthritis, axial spondyloarthritis, psoriasis, and MS. Closed beta · 2026. ### Neural Omega Research — For researchers and pharma - [MAR Platform](https://neuralomega.com/en/research/mar-platform): Multimodal Autoimmune Research platform. Infrastructure for designing, conducting, and executing clinical, observational, and real-world evidence studies on autoimmune disease. OMOP and FHIR-aligned data structures, multi-disease cohort assembly, a molecular mimicry sequence repository (largest in Europe), and native integration of patient-reported outcomes from Maia. Aligned with the EHDS 2029 framework for cross-border secondary use studies. In development · 2027. - [Massa](https://neuralomega.com/en/research/mimicry): AI engine for detecting molecular mimicry between pathogens and human proteins — one of the most structurally compelling hypotheses for what triggers autoimmune disease. Powers a target discovery pipeline from hypothesis to drug candidate. Built around Cypher, a sequence similarity detection engine capable of scanning the entire human proteome against a pathogen proteome in under 2 seconds (11,700 sequences/second). Designed for pharma R&D collaboration, with clear IP boundaries and regulatory-compliant documentation from day one. In optimisation · 2027. --- ## Observatory Long-form original research, structural analysis, and data journalism on the problems Neural Omega is building to solve. Intended to be cited by clinicians, researchers, and policymakers. Four editorial themes: the diagnosis gap, the architecture of autoimmunity, the EHDS and data governance, and what patients actually need from the healthcare system. - [Observatory index](https://neuralomega.com/en/observatory): All published essays, latest first. - [Why does it still take 7 years to diagnose ankylosing spondylitis?](https://neuralomega.com/en/observatory/01): Analysis of why the autoimmune diagnosis gap exists, why it is unequal across conditions, and what would need to change. The average European autoimmune patient sees 5–7 specialists before a confirmed diagnosis. Three structural causes: referral fragmentation, absence of longitudinal cross-specialty records, and the complete exclusion of the patient's voice from the clinical protocol. Author: Pedro Bernardo Martín-Borregón. --- ## About - [About Neural Omega](https://neuralomega.com/en/about): Mission, thesis, product architecture, team, and backing. Explains why four products on a single European data layer — rather than four isolated tools — is the design decision that makes autoimmune medicine buildable at European scale. - [Contact](https://neuralomega.com/en/contact): How to reach Neural Omega for clinical partnerships, research collaboration, investor enquiries, and patient association cooperation. --- ## Site - Homepage: [https://neuralomega.com/en](https://neuralomega.com/en) - Available in six languages: Spanish (es), English (en), Catalan (ca), French (fr), German (de), Japanese (ja) - Spanish is the primary locale; English is the x-default for international crawlers - Japanese locale is strategically active — BioJapan is a relevant target market